---

Unveiling the intricate layers of Oxford Biomedica’s 2023 financial results, this report delves into the strategic shifts, financial health, and forward-looking projections that define the company’s trajectory in the evolving landscape of cell and gene therapy.

---

In 2023, Oxford Biomedica PLC experienced a transformative year, marked by strategic shifts towards becoming a global, pure-play cell and gene therapy Contract Development and Manufacturing Organization (CDMO). Despite the backdrop of operational challenges, including significant financial losses primarily due to impairment charges in the US, the company has reinforced its market position with robust growth in contracted client orders and an expanded business development pipeline.

Financial Performance

OXB reported a 36% decline in total revenues, dropping from £140 million in 2022 to £89.5 million in 2023. This sharp decrease was largely due to the non-recurrence of COVID-19 vaccine manufacturing revenues. However, the core business revenues, excluding these non-recurring revenues, showed a slight increase, indicating stability in the company’s primary operations.

Cost Management and Profitability

The operational restructuring initiated under the “One OXB” strategy has led to a significant reduction in the ongoing cost base, approximately £30 million annually compared to 2023. This restructuring, however, couldn’t offset the substantial operating loss of £184.2 million, which included a hefty £99.3 million impairment charge related to the cessation of revenues from Homology Medicines Inc. (Homology).

Risk Factors

The primary risk confronting OXB stems from its dependency on the cell and gene therapy market’s volatile nature and the regulatory landscape. Additionally, the substantial impairment reflecting operational risks in the US highlights vulnerabilities in relying heavily on specific clients or projects.

Under the leadership of CEO Dr. Frank Mathias, OXB has streamlined operations and emphasized its core CDMO services. Despite the financial setbacks in 2023, management remains committed to its strategic objectives, aiming for a rebound in profitability and market expansion through the acquisition of ABL Europe and bolstering operations in the EU.

Investment Highlights

OXB’s investment appeal is anchored in its robust pipeline growth, strategic acquisitions like Oxford Biomedica (France), and the potential market growth in cell and gene therapies. Notably, the contracted value of client orders increased by over 50% to £131 million in 2023, underscoring strong commercial momentum.

Historical Performance Review

Over the past years, OXB has demonstrated resilience and adaptability, navigating through market fluctuations and regulatory challenges. The strategic focus shift towards a pure-play CDMO model marks a significant pivot intended to harness long-term growth opportunities in the burgeoning field of gene therapies.

Liquidity and Capital Resources

As of December 31, 2023, OXB reported a cash balance of £103.7 million, a decrease from £141.3 million in 2022. This reduction reflects the cash burn amid operational challenges and significant investment in strategic initiatives. The company’s liquidity position, supported by stringent cost control measures, remains adequate to meet its short-term obligations.

Outlook and Future Projections

OXB reaffirms its financial guidance for 2024, projecting total group revenues between £126 million and £134 million, with expectations of returning to EBITDA profitability by 2025. The strategic integrations and expansions, particularly the inclusion of Oxford Biomedica (France), are anticipated to catalyze growth and enhance operational efficiencies.

Key Takeaways for Investors

Oxford Biomedica stands at a pivotal juncture, with its strategic reorientation poised to capitalize on the expanding opportunities within the cell and gene therapy sector. While the financial performance in 2023 raises concerns, the proactive strategic measures and robust pipeline development herald potential for recovery and growth. Investors should weigh the operational risks against the strategic initiatives aimed at long-term value creation.